Research Article Details
| Article ID: | A27744 |
| PMID: | 17542278 |
| Source: | Rev Gastroenterol Mex |
| Title: | [Prevalence of NAFLD and metabolic syndrome in asymtomatics subjects]. |
| Abstract: | UNLABELLED: Non Alcoholic Fatty Liver Disease (NAFLD) is a frequent entity to progress to liver fibrosis and cirrhosis, and it is associated with several metabolic disturbances. The insulin resistance is often considered the link between metabolic disturbances and NAFLD. The aim of this study was to determine the prevalence of NAFLD in healthy population and the prevalence of metabolic syndrome in this patients. The associated factors to develop liver cirrhosis were identified. METHODS: 2,503 records were reviewed and the presence of steatosis was determined by ultrasonography. A clinical and biochemical examination was carried out and the metabolic criteria were defined according to the ATP III. RESULTS: 427 (17.05%) patients with NAFLD were detected. 359 (14.3%) with NAFLD were included, the mean age was 46.26 +/- 9.85 years. Overweight was present in 46.79% and obesity in 36.49% of patients. The association between DM, HAS, high levels of cholesterol and triglicerides was found in 3.6, 13.6, 63 and 43%, respectively. Steatohepatitis was found in in 34% of patients high levels of AST. AST/ALT ratio > 1 was detected in 76 patients (21.16%). According to the ATP III criteria, the prevalence of metabolic syndrome in patients with NAFLD was 22.8%. CONCLUSIONS: The frequency of NAFLD and metabolic syndrome in this study was 14.3% and 22.8%, respectively. Overweight, obesity and dyslipidemia were the main associated factors to NAFLD. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |